AI-Fueled Generate Maps Out Path To Clinic Over Next 24 Months

The biotech company already has a candidate with a tough target in the clinic for COVID-19 and plans to have four to six candidates in the clinic over the next two years following a $273m series C round.

Generate Biomedicines announced a $273m series C funding round • Source: Shutterstock

Just a year after picking the first targets for its artificial intelligence-based drug discovery platform, Generate Biomedicines has already taken its first product candidate into the clinic, and it now plans to use a new financing round to advance more, with the potential to have as many as half a dozen candidates in human trials during the next two years.

The Flagship Pioneering-spawned biotech company said 14 September that it raised $273m in a series C venture capital round, bringing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Digital Technologies